首页> 外文期刊>Current pharmaceutical design >Metabolic syndrome and non-cardiac vascular diseases: An update from human studies
【24h】

Metabolic syndrome and non-cardiac vascular diseases: An update from human studies

机译:代谢综合征和非心血管疾病:人体研究的最新进展

获取原文
获取原文并翻译 | 示例
           

摘要

The metabolic syndrome (MetS) is characterized by a cluster of risk factors including central obesity, hypertension, dyslipidemia and insulin resistance, The MetS is associated with an increased risk for cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM). Several international organizations have defined MetS using different diagnostic criteria that produced discrepancies in the results of previous studies, thus leading to the latest Joint Interim Societies (JIS) MetS definition. Other risk factors than the diagnostic criteria that have been associated with MetS include lipid abnormalities, uric acid, liver function, prothrombotic factors, cytokines, adipokines, vitamin D, arterial stiffness, polycystic ovary syndrome and obstructive sleep apnea. Apart from CVD and T2DM, MetS has been related to non-cardiac vascular diseases and in particular to stroke, carotid artery disease, peripheral artery disease, chronic kidney disease, atherosclerotic renal artery stenosis and abdominal aortic aneurysms. In this narrative review, the associations of these diseases with MetS and its components will be discussed. These associations may further increase CVD risk in MetS patients, highlighting the importance of treating such high-risk individuals early and "to target". In this context, multifactorial treatment including a statin has been proven beneficial, and thus should be considered, in MetS patients.
机译:代谢综合症(MetS)的特征是一系列风险因素,包括中枢性肥胖,高血压,血脂异常和胰岛素抵抗。MetS与心血管疾病(CVD)和2型糖尿病(T2DM)的风险增加相关。几个国际组织已经使用不同的诊断标准对MetS进行了定义,这些诊断标准在先前的研究结果中产生了差异,因此导致了最新的联合临时社会(JIS)MetS定义。与MetS相关的诊断标准以外的其他危险因素包括脂质异常,尿酸,肝功能,血栓形成因子,细胞因子,脂肪因子,维生素D,动脉僵硬度,多囊卵巢综合征和阻塞性睡眠呼吸暂停。除了CVD和T2DM,MetS还与非心血管疾病有关,特别是与中风,颈动脉疾病,外周动脉疾病,慢性肾脏疾病,动脉粥样硬化性肾动脉狭窄和腹主动脉瘤有关。在这篇叙述性综述中,将讨论这些疾病与MetS及其组成部分的关系。这些关联可能会进一步增加MetS患者的CVD风险,突出了及早治疗并“靶向”这类高风险个体的重要性。在这种情况下,已证明包括他汀类药物在内的多因素治疗在MetS患者中是有益的,因此应予以考虑。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号